0.595
-0.0005 (-0.08%)
-0.0005 (-0.08%)
Upgrade to Real-Time
Afterhours
| Volume | 88,544 |
|
|||||
| News | - | ||||||
| Day High | 0.63 | Low High |
|||||
| Day Low | 0.5711 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vaccinex Inc | VCNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0005 | -0.08% | 0.595 | 17:13:48 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.60 | 0.5711 | 0.63 | 0.595 | 0.5955 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 243 | 88,544 | $ 0.594524 | $ 52,642 | - | 0.41 - 2.28 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:01 | 30 | $ 0.5955 | USD |
Period:
Draw Mode:
Vaccinex Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 29.68M | 49.88M | 30.21M | $ 900.00k | $ - | -0.79 | -1.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 5.56M | 0.70% |
Vaccinex News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VCNX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.5915 | 0.635 | 0.56 | 0.591733 | 60,612 | 0.0035 | 0.59% |
| 1 Month | 0.62 | 0.675 | 0.557 | 0.6104015 | 46,698 | -0.025 | -4.03% |
| 3 Months | 0.57 | 0.779899 | 0.41 | 0.6123672 | 56,114 | 0.025 | 4.39% |
| 6 Months | 1.06 | 1.50 | 0.41 | 0.8186435 | 97,793 | -0.465 | -43.87% |
| 1 Year | 1.13 | 2.28 | 0.41 | 1.34 | 189,516 | -0.535 | -47.35% |
| 3 Years | 7.32 | 11.00 | 0.41 | 3.75 | 813,987 | -6.73 | -91.87% |
| 5 Years | 12.00 | 12.23 | 0.41 | 3.78 | 553,250 | -11.41 | -95.04% |
Vaccinex Description
| Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements. |